nodes	percent_of_prediction	percent_of_DWPC	metapath
Fesoterodine—CHRM3—nephrolithiasis	0.827	1	CbGaD
Fesoterodine—Dry cough—Hydrochlorothiazide—nephrolithiasis	0.0165	0.184	CcSEcCtD
Fesoterodine—Airway obstruction NOS—Hydrochlorothiazide—nephrolithiasis	0.0155	0.173	CcSEcCtD
Fesoterodine—Obstructive airways disorder—Hydrochlorothiazide—nephrolithiasis	0.0112	0.125	CcSEcCtD
Fesoterodine—CHRM3—ureter—nephrolithiasis	0.00983	0.554	CbGeAlD
Fesoterodine—CHRM4—Muscarinic acetylcholine receptors—CHRM3—nephrolithiasis	0.00737	0.123	CbGpPWpGaD
Fesoterodine—CHRM5—Muscarinic acetylcholine receptors—CHRM3—nephrolithiasis	0.00706	0.118	CbGpPWpGaD
Fesoterodine—CHRM1—Muscarinic acetylcholine receptors—CHRM3—nephrolithiasis	0.00497	0.0828	CbGpPWpGaD
Fesoterodine—CHRM2—Muscarinic acetylcholine receptors—CHRM3—nephrolithiasis	0.00491	0.0817	CbGpPWpGaD
Fesoterodine—Gamma-glutamyltransferase increased—Hydrochlorothiazide—nephrolithiasis	0.0031	0.0346	CcSEcCtD
Fesoterodine—Gastrooesophageal reflux disease—Hydrochlorothiazide—nephrolithiasis	0.00282	0.0315	CcSEcCtD
Fesoterodine—Tolterodine—CHRM3—nephrolithiasis	0.0028	0.5	CrCbGaD
Fesoterodine—Disopyramide—CHRM3—nephrolithiasis	0.0028	0.5	CrCbGaD
Fesoterodine—Gastroenteritis—Hydrochlorothiazide—nephrolithiasis	0.00209	0.0233	CcSEcCtD
Fesoterodine—Face oedema—Hydrochlorothiazide—nephrolithiasis	0.00179	0.0199	CcSEcCtD
Fesoterodine—CYP3A4—urine—nephrolithiasis	0.00176	0.0989	CbGeAlD
Fesoterodine—CYP2D6—urine—nephrolithiasis	0.00173	0.0974	CbGeAlD
Fesoterodine—Dry skin—Hydrochlorothiazide—nephrolithiasis	0.0017	0.0189	CcSEcCtD
Fesoterodine—Abdominal pain upper—Hydrochlorothiazide—nephrolithiasis	0.00169	0.0189	CcSEcCtD
Fesoterodine—Alanine aminotransferase increased—Hydrochlorothiazide—nephrolithiasis	0.00163	0.0182	CcSEcCtD
Fesoterodine—CHRM4—Monoamine GPCRs—CHRM3—nephrolithiasis	0.00163	0.0271	CbGpPWpGaD
Fesoterodine—CHRM5—Monoamine GPCRs—CHRM3—nephrolithiasis	0.00156	0.026	CbGpPWpGaD
Fesoterodine—Angina pectoris—Hydrochlorothiazide—nephrolithiasis	0.00156	0.0174	CcSEcCtD
Fesoterodine—Dysuria—Hydrochlorothiazide—nephrolithiasis	0.0015	0.0167	CcSEcCtD
Fesoterodine—Upper respiratory tract infection—Hydrochlorothiazide—nephrolithiasis	0.00149	0.0166	CcSEcCtD
Fesoterodine—Urinary tract infection—Hydrochlorothiazide—nephrolithiasis	0.00139	0.0155	CcSEcCtD
Fesoterodine—CHRM4—Amine ligand-binding receptors—CHRM3—nephrolithiasis	0.00137	0.0228	CbGpPWpGaD
Fesoterodine—CHRM5—Amine ligand-binding receptors—CHRM3—nephrolithiasis	0.00131	0.0218	CbGpPWpGaD
Fesoterodine—Oedema peripheral—Hydrochlorothiazide—nephrolithiasis	0.00126	0.0141	CcSEcCtD
Fesoterodine—CHRM1—Monoamine GPCRs—CHRM3—nephrolithiasis	0.0011	0.0183	CbGpPWpGaD
Fesoterodine—Flatulence—Hydrochlorothiazide—nephrolithiasis	0.0011	0.0123	CcSEcCtD
Fesoterodine—Dysgeusia—Hydrochlorothiazide—nephrolithiasis	0.00109	0.0122	CcSEcCtD
Fesoterodine—CHRM2—Monoamine GPCRs—CHRM3—nephrolithiasis	0.00108	0.0181	CbGpPWpGaD
Fesoterodine—Back pain—Hydrochlorothiazide—nephrolithiasis	0.00108	0.012	CcSEcCtD
Fesoterodine—Vision blurred—Hydrochlorothiazide—nephrolithiasis	0.00105	0.0117	CcSEcCtD
Fesoterodine—Angioedema—Hydrochlorothiazide—nephrolithiasis	0.00102	0.0114	CcSEcCtD
Fesoterodine—Vertigo—Hydrochlorothiazide—nephrolithiasis	0.001	0.0112	CcSEcCtD
Fesoterodine—CHRM4—Calcium Regulation in the Cardiac Cell—RGS14—nephrolithiasis	0.000999	0.0166	CbGpPWpGaD
Fesoterodine—Palpitations—Hydrochlorothiazide—nephrolithiasis	0.000985	0.011	CcSEcCtD
Fesoterodine—Cough—Hydrochlorothiazide—nephrolithiasis	0.000973	0.0108	CcSEcCtD
Fesoterodine—CHRM5—Calcium Regulation in the Cardiac Cell—RGS14—nephrolithiasis	0.000957	0.0159	CbGpPWpGaD
Fesoterodine—Chest pain—Hydrochlorothiazide—nephrolithiasis	0.000949	0.0106	CcSEcCtD
Fesoterodine—Dry mouth—Hydrochlorothiazide—nephrolithiasis	0.000928	0.0104	CcSEcCtD
Fesoterodine—CHRM1—Amine ligand-binding receptors—CHRM3—nephrolithiasis	0.000924	0.0154	CbGpPWpGaD
Fesoterodine—Confusional state—Hydrochlorothiazide—nephrolithiasis	0.000917	0.0102	CcSEcCtD
Fesoterodine—CHRM2—Amine ligand-binding receptors—CHRM3—nephrolithiasis	0.000912	0.0152	CbGpPWpGaD
Fesoterodine—Tachycardia—Hydrochlorothiazide—nephrolithiasis	0.000888	0.0099	CcSEcCtD
Fesoterodine—Insomnia—Hydrochlorothiazide—nephrolithiasis	0.000823	0.00918	CcSEcCtD
Fesoterodine—Somnolence—Hydrochlorothiazide—nephrolithiasis	0.000809	0.00902	CcSEcCtD
Fesoterodine—Dyspepsia—Hydrochlorothiazide—nephrolithiasis	0.000801	0.00893	CcSEcCtD
Fesoterodine—Fatigue—Hydrochlorothiazide—nephrolithiasis	0.000784	0.00875	CcSEcCtD
Fesoterodine—CHRM3—renal system—nephrolithiasis	0.000782	0.0441	CbGeAlD
Fesoterodine—Constipation—Hydrochlorothiazide—nephrolithiasis	0.000778	0.00868	CcSEcCtD
Fesoterodine—CHRM3—kidney—nephrolithiasis	0.000756	0.0426	CbGeAlD
Fesoterodine—Feeling abnormal—Hydrochlorothiazide—nephrolithiasis	0.00075	0.00836	CcSEcCtD
Fesoterodine—Gastrointestinal pain—Hydrochlorothiazide—nephrolithiasis	0.000744	0.0083	CcSEcCtD
Fesoterodine—Urticaria—Hydrochlorothiazide—nephrolithiasis	0.000723	0.00806	CcSEcCtD
Fesoterodine—Abdominal pain—Hydrochlorothiazide—nephrolithiasis	0.000719	0.00802	CcSEcCtD
Fesoterodine—CHRM4—G alpha (i) signalling events—RGS14—nephrolithiasis	0.000694	0.0115	CbGpPWpGaD
Fesoterodine—CHRM1—Calcium Regulation in the Cardiac Cell—RGS14—nephrolithiasis	0.000674	0.0112	CbGpPWpGaD
Fesoterodine—CHRM3—Calcium Regulation in the Cardiac Cell—RGS14—nephrolithiasis	0.000671	0.0112	CbGpPWpGaD
Fesoterodine—Hypersensitivity—Hydrochlorothiazide—nephrolithiasis	0.00067	0.00748	CcSEcCtD
Fesoterodine—CHRM2—Calcium Regulation in the Cardiac Cell—RGS14—nephrolithiasis	0.000665	0.0111	CbGpPWpGaD
Fesoterodine—Asthenia—Hydrochlorothiazide—nephrolithiasis	0.000653	0.00728	CcSEcCtD
Fesoterodine—Pruritus—Hydrochlorothiazide—nephrolithiasis	0.000644	0.00718	CcSEcCtD
Fesoterodine—Diarrhoea—Hydrochlorothiazide—nephrolithiasis	0.000622	0.00694	CcSEcCtD
Fesoterodine—Dizziness—Hydrochlorothiazide—nephrolithiasis	0.000602	0.00671	CcSEcCtD
Fesoterodine—Rash—Hydrochlorothiazide—nephrolithiasis	0.000574	0.0064	CcSEcCtD
Fesoterodine—Dermatitis—Hydrochlorothiazide—nephrolithiasis	0.000573	0.00639	CcSEcCtD
Fesoterodine—Headache—Hydrochlorothiazide—nephrolithiasis	0.00057	0.00636	CcSEcCtD
Fesoterodine—Nausea—Hydrochlorothiazide—nephrolithiasis	0.00054	0.00603	CcSEcCtD
Fesoterodine—CHRM5—G alpha (q) signalling events—DGKH—nephrolithiasis	0.000539	0.00897	CbGpPWpGaD
Fesoterodine—CHRM4—Regulation of Actin Cytoskeleton—CHRM3—nephrolithiasis	0.000488	0.00812	CbGpPWpGaD
Fesoterodine—CHRM4—Calcium Regulation in the Cardiac Cell—CHRM3—nephrolithiasis	0.000488	0.00812	CbGpPWpGaD
Fesoterodine—CHRM5—Gastrin-CREB signalling pathway via PKC and MAPK—DGKH—nephrolithiasis	0.000482	0.00802	CbGpPWpGaD
Fesoterodine—CHRM2—GPCRs, Other—CHRM3—nephrolithiasis	0.000482	0.00802	CbGpPWpGaD
Fesoterodine—CHRM5—Regulation of Actin Cytoskeleton—CHRM3—nephrolithiasis	0.000467	0.00778	CbGpPWpGaD
Fesoterodine—CHRM5—Calcium Regulation in the Cardiac Cell—CHRM3—nephrolithiasis	0.000467	0.00778	CbGpPWpGaD
Fesoterodine—CHRM2—G alpha (i) signalling events—RGS14—nephrolithiasis	0.000462	0.00769	CbGpPWpGaD
Fesoterodine—CYP3A4—renal system—nephrolithiasis	0.000429	0.0242	CbGeAlD
Fesoterodine—CYP2D6—renal system—nephrolithiasis	0.000423	0.0238	CbGeAlD
Fesoterodine—CYP3A4—kidney—nephrolithiasis	0.000415	0.0234	CbGeAlD
Fesoterodine—CYP2D6—kidney—nephrolithiasis	0.000409	0.023	CbGeAlD
Fesoterodine—CHRM5—G alpha (q) signalling events—CHRM3—nephrolithiasis	0.00039	0.00648	CbGpPWpGaD
Fesoterodine—CHRM1—G alpha (q) signalling events—DGKH—nephrolithiasis	0.000379	0.00632	CbGpPWpGaD
Fesoterodine—CHRM3—G alpha (q) signalling events—DGKH—nephrolithiasis	0.000378	0.00629	CbGpPWpGaD
Fesoterodine—CHRM5—Gastrin-CREB signalling pathway via PKC and MAPK—CHRM3—nephrolithiasis	0.000348	0.0058	CbGpPWpGaD
Fesoterodine—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—DGKH—nephrolithiasis	0.000339	0.00565	CbGpPWpGaD
Fesoterodine—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—DGKH—nephrolithiasis	0.000338	0.00563	CbGpPWpGaD
Fesoterodine—ABCB1—nephron tubule—nephrolithiasis	0.000334	0.0188	CbGeAlD
Fesoterodine—CHRM1—Calcium Regulation in the Cardiac Cell—CHRM3—nephrolithiasis	0.000329	0.00548	CbGpPWpGaD
Fesoterodine—CHRM1—Regulation of Actin Cytoskeleton—CHRM3—nephrolithiasis	0.000329	0.00548	CbGpPWpGaD
Fesoterodine—CHRM2—Calcium Regulation in the Cardiac Cell—CHRM3—nephrolithiasis	0.000325	0.00541	CbGpPWpGaD
Fesoterodine—CHRM2—Regulation of Actin Cytoskeleton—CHRM3—nephrolithiasis	0.000325	0.00541	CbGpPWpGaD
Fesoterodine—CHRM4—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.000314	0.00523	CbGpPWpGaD
Fesoterodine—ABCB1—renal system—nephrolithiasis	0.000304	0.0171	CbGeAlD
Fesoterodine—CHRM5—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.000301	0.00501	CbGpPWpGaD
Fesoterodine—ABCB1—kidney—nephrolithiasis	0.000294	0.0166	CbGeAlD
Fesoterodine—ABCB1—cortex of kidney—nephrolithiasis	0.000286	0.0161	CbGeAlD
Fesoterodine—CHRM1—G alpha (q) signalling events—CHRM3—nephrolithiasis	0.000274	0.00457	CbGpPWpGaD
Fesoterodine—CYP2D6—Biological oxidations—SLC26A1—nephrolithiasis	0.000271	0.00452	CbGpPWpGaD
Fesoterodine—CHRM4—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.000269	0.00448	CbGpPWpGaD
Fesoterodine—CHRM5—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.000258	0.00429	CbGpPWpGaD
Fesoterodine—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—CHRM3—nephrolithiasis	0.000245	0.00408	CbGpPWpGaD
Fesoterodine—CHRM4—GPCR downstream signaling—RGS14—nephrolithiasis	0.000237	0.00395	CbGpPWpGaD
Fesoterodine—CHRM5—GPCR downstream signaling—RGS14—nephrolithiasis	0.000227	0.00378	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling by GPCR—RGS14—nephrolithiasis	0.000216	0.00359	CbGpPWpGaD
Fesoterodine—CHRM1—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.000212	0.00353	CbGpPWpGaD
Fesoterodine—CHRM2—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.000209	0.00348	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling by GPCR—RGS14—nephrolithiasis	0.000206	0.00344	CbGpPWpGaD
Fesoterodine—CHRM4—GPCR ligand binding—CHRM3—nephrolithiasis	0.000205	0.00341	CbGpPWpGaD
Fesoterodine—CHRM5—GPCR ligand binding—CHRM3—nephrolithiasis	0.000196	0.00327	CbGpPWpGaD
Fesoterodine—CHRM4—GPCR ligand binding—PTH—nephrolithiasis	0.000188	0.00312	CbGpPWpGaD
Fesoterodine—ABCB1—Transmembrane transport of small molecules—CLCN5—nephrolithiasis	0.000183	0.00305	CbGpPWpGaD
Fesoterodine—ABCB1—Transmembrane transport of small molecules—CLCN4—nephrolithiasis	0.000183	0.00305	CbGpPWpGaD
Fesoterodine—CHRM1—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.000182	0.00302	CbGpPWpGaD
Fesoterodine—CHRM5—GPCR ligand binding—PTH—nephrolithiasis	0.00018	0.00299	CbGpPWpGaD
Fesoterodine—CHRM2—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.000179	0.00298	CbGpPWpGaD
Fesoterodine—CYP3A4—Biological oxidations—SLC26A1—nephrolithiasis	0.000177	0.00295	CbGpPWpGaD
Fesoterodine—ABCB1—Transmembrane transport of small molecules—SLC26A6—nephrolithiasis	0.000163	0.00271	CbGpPWpGaD
Fesoterodine—CHRM4—GPCR downstream signaling—DGKH—nephrolithiasis	0.00016	0.00267	CbGpPWpGaD
Fesoterodine—CHRM1—GPCR downstream signaling—RGS14—nephrolithiasis	0.00016	0.00266	CbGpPWpGaD
Fesoterodine—CHRM3—GPCR downstream signaling—RGS14—nephrolithiasis	0.00016	0.00266	CbGpPWpGaD
Fesoterodine—CHRM2—GPCR downstream signaling—RGS14—nephrolithiasis	0.000158	0.00263	CbGpPWpGaD
Fesoterodine—CHRM5—GPCR downstream signaling—DGKH—nephrolithiasis	0.000154	0.00256	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—ADCY10—nephrolithiasis	0.00015	0.00249	CbGpPWpGaD
Fesoterodine—ABCB1—Transmembrane transport of small molecules—SLC3A1—nephrolithiasis	0.000149	0.00248	CbGpPWpGaD
Fesoterodine—ABCB1—Transmembrane transport of small molecules—SLC34A3—nephrolithiasis	0.000149	0.00248	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling by GPCR—DGKH—nephrolithiasis	0.000146	0.00242	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling by GPCR—RGS14—nephrolithiasis	0.000145	0.00242	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling by GPCR—RGS14—nephrolithiasis	0.000145	0.00241	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling by GPCR—RGS14—nephrolithiasis	0.000143	0.00239	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—ADCY10—nephrolithiasis	0.000143	0.00239	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling by GPCR—DGKH—nephrolithiasis	0.000139	0.00232	CbGpPWpGaD
Fesoterodine—CHRM1—GPCR ligand binding—CHRM3—nephrolithiasis	0.000138	0.0023	CbGpPWpGaD
Fesoterodine—CHRM2—GPCR ligand binding—CHRM3—nephrolithiasis	0.000137	0.00227	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—RGS14—nephrolithiasis	0.000127	0.00212	CbGpPWpGaD
Fesoterodine—CHRM1—GPCR ligand binding—PTH—nephrolithiasis	0.000127	0.00211	CbGpPWpGaD
Fesoterodine—CHRM3—GPCR ligand binding—PTH—nephrolithiasis	0.000126	0.0021	CbGpPWpGaD
Fesoterodine—CHRM2—GPCR ligand binding—PTH—nephrolithiasis	0.000125	0.00208	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—RGS14—nephrolithiasis	0.000122	0.00203	CbGpPWpGaD
Fesoterodine—CHRM4—GPCR downstream signaling—CHRM3—nephrolithiasis	0.000116	0.00193	CbGpPWpGaD
Fesoterodine—ABCB1—Transmembrane transport of small molecules—SLC22A12—nephrolithiasis	0.000113	0.00188	CbGpPWpGaD
Fesoterodine—ABCB1—Transmembrane transport of small molecules—SLC34A1—nephrolithiasis	0.000113	0.00188	CbGpPWpGaD
Fesoterodine—CHRM5—GPCR downstream signaling—CHRM3—nephrolithiasis	0.000111	0.00185	CbGpPWpGaD
Fesoterodine—CHRM1—GPCR downstream signaling—DGKH—nephrolithiasis	0.000108	0.0018	CbGpPWpGaD
Fesoterodine—CHRM3—GPCR downstream signaling—DGKH—nephrolithiasis	0.000108	0.00179	CbGpPWpGaD
Fesoterodine—CHRM2—GPCR downstream signaling—DGKH—nephrolithiasis	0.000107	0.00178	CbGpPWpGaD
Fesoterodine—CHRM4—GPCR downstream signaling—PTH—nephrolithiasis	0.000106	0.00177	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling by GPCR—CHRM3—nephrolithiasis	0.000105	0.00175	CbGpPWpGaD
Fesoterodine—ABCB1—Transmembrane transport of small molecules—SLC2A9—nephrolithiasis	0.000105	0.00175	CbGpPWpGaD
Fesoterodine—ABCB1—Transmembrane transport of small molecules—SLC26A1—nephrolithiasis	0.000105	0.00175	CbGpPWpGaD
Fesoterodine—CHRM3—Metabolism—GRHPR—nephrolithiasis	0.000102	0.0017	CbGpPWpGaD
Fesoterodine—CHRM5—GPCR downstream signaling—PTH—nephrolithiasis	0.000102	0.00169	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—ADCY10—nephrolithiasis	0.000101	0.00168	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling by GPCR—CHRM3—nephrolithiasis	0.000101	0.00168	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—ADCY10—nephrolithiasis	0.000101	0.00168	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—ADCY10—nephrolithiasis	9.97e-05	0.00166	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling by GPCR—DGKH—nephrolithiasis	9.82e-05	0.00163	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling by GPCR—DGKH—nephrolithiasis	9.79e-05	0.00163	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling by GPCR—DGKH—nephrolithiasis	9.69e-05	0.00161	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling by GPCR—PTH—nephrolithiasis	9.63e-05	0.0016	CbGpPWpGaD
Fesoterodine—ABCB1—Transmembrane transport of small molecules—SLC7A9—nephrolithiasis	9.37e-05	0.00156	CbGpPWpGaD
Fesoterodine—ABCB1—Transmembrane transport of small molecules—ATP6V0A4—nephrolithiasis	9.37e-05	0.00156	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling by GPCR—PTH—nephrolithiasis	9.22e-05	0.00153	CbGpPWpGaD
Fesoterodine—CHRM3—Metabolism—AGXT—nephrolithiasis	9.12e-05	0.00152	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—DGKH—nephrolithiasis	8.6e-05	0.00143	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—ATP6V0A4—nephrolithiasis	8.6e-05	0.00143	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—RGS14—nephrolithiasis	8.59e-05	0.00143	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—RGS14—nephrolithiasis	8.56e-05	0.00142	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—RGS14—nephrolithiasis	8.48e-05	0.00141	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—ATP6V0A4—nephrolithiasis	8.24e-05	0.00137	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—DGKH—nephrolithiasis	8.24e-05	0.00137	CbGpPWpGaD
Fesoterodine—CHRM1—GPCR downstream signaling—CHRM3—nephrolithiasis	7.82e-05	0.0013	CbGpPWpGaD
Fesoterodine—CHRM3—Metabolism—APRT—nephrolithiasis	7.76e-05	0.00129	CbGpPWpGaD
Fesoterodine—CHRM3—Metabolism—SLC26A1—nephrolithiasis	7.76e-05	0.00129	CbGpPWpGaD
Fesoterodine—CHRM2—GPCR downstream signaling—CHRM3—nephrolithiasis	7.72e-05	0.00128	CbGpPWpGaD
Fesoterodine—ABCB1—Transmembrane transport of small molecules—AQP1—nephrolithiasis	7.49e-05	0.00125	CbGpPWpGaD
Fesoterodine—CHRM1—GPCR downstream signaling—PTH—nephrolithiasis	7.15e-05	0.00119	CbGpPWpGaD
Fesoterodine—CHRM3—GPCR downstream signaling—PTH—nephrolithiasis	7.13e-05	0.00119	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling by GPCR—CHRM3—nephrolithiasis	7.1e-05	0.00118	CbGpPWpGaD
Fesoterodine—CHRM2—GPCR downstream signaling—PTH—nephrolithiasis	7.06e-05	0.00117	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling by GPCR—CHRM3—nephrolithiasis	7.01e-05	0.00117	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—GRHPR—nephrolithiasis	6.5e-05	0.00108	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling by GPCR—PTH—nephrolithiasis	6.49e-05	0.00108	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling by GPCR—PTH—nephrolithiasis	6.47e-05	0.00108	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling by GPCR—PTH—nephrolithiasis	6.41e-05	0.00107	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—CHRM3—nephrolithiasis	6.22e-05	0.00104	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—GRHPR—nephrolithiasis	6.12e-05	0.00102	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—CHRM3—nephrolithiasis	5.96e-05	0.000991	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—ATP6V0A4—nephrolithiasis	5.8e-05	0.000966	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—DGKH—nephrolithiasis	5.8e-05	0.000966	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—AGXT—nephrolithiasis	5.79e-05	0.000964	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—DGKH—nephrolithiasis	5.78e-05	0.000962	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—ATP6V0A4—nephrolithiasis	5.78e-05	0.000962	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—ATP6V0A4—nephrolithiasis	5.73e-05	0.000953	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—DGKH—nephrolithiasis	5.73e-05	0.000953	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—PTH—nephrolithiasis	5.69e-05	0.000947	CbGpPWpGaD
Fesoterodine—CHRM3—Metabolism—AQP1—nephrolithiasis	5.53e-05	0.00092	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—AGXT—nephrolithiasis	5.46e-05	0.000908	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—PTH—nephrolithiasis	5.45e-05	0.000907	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—SLC26A1—nephrolithiasis	4.92e-05	0.000819	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—APRT—nephrolithiasis	4.92e-05	0.000819	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—SLC26A1—nephrolithiasis	4.64e-05	0.000772	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—APRT—nephrolithiasis	4.64e-05	0.000772	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—CHRM3—nephrolithiasis	4.19e-05	0.000698	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—CHRM3—nephrolithiasis	4.14e-05	0.000689	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—GRHPR—nephrolithiasis	4e-05	0.000666	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—PTH—nephrolithiasis	3.84e-05	0.000638	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—PTH—nephrolithiasis	3.82e-05	0.000636	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—PTH—nephrolithiasis	3.79e-05	0.00063	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—AGXT—nephrolithiasis	3.57e-05	0.000594	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—AQP1—nephrolithiasis	3.51e-05	0.000584	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—AQP1—nephrolithiasis	3.31e-05	0.00055	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—CHRM3—nephrolithiasis	3.17e-05	0.000528	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—SLC26A1—nephrolithiasis	3.03e-05	0.000505	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—APRT—nephrolithiasis	3.03e-05	0.000505	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—CHRM3—nephrolithiasis	2.99e-05	0.000498	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—SPP1—nephrolithiasis	2.86e-05	0.000475	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—SPP1—nephrolithiasis	2.73e-05	0.000455	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—AQP1—nephrolithiasis	2.16e-05	0.00036	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—CHRM3—nephrolithiasis	1.95e-05	0.000325	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—SPP1—nephrolithiasis	1.93e-05	0.000321	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—SPP1—nephrolithiasis	1.92e-05	0.000319	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—SPP1—nephrolithiasis	1.9e-05	0.000316	CbGpPWpGaD
